Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication 
CC12.1
Potential treatment - pre-clinical evidence Experimental Antiviral
Regdanvimab
Authorized Experimental Antiviral
S96
Potential treatment - pre-clinical evidence Experimental Antiviral
1-{4-[(Methoxyacetyl)amino]phenyl}-N-(3-methoxypropyl)cyclohexanecarboxamide
Potential treatment - theoretical effect Experimental Antiviral
mAb 2-43
Potential treatment - pre-clinical evidence Experimental Antiviral
7-methyl-guanosine-5′-triphosphate-5′-guanosine
Potential treatment - theoretical effect Experimental Antiviral
MRT5500
Potential treatment - pre-clinical evidence Experimental Vaccine
F12
Potential treatment - pre-clinical evidence Experimental Antiviral
D3
Potential treatment - pre-clinical evidence Experimental Antiviral
CR3022
Potential treatment - pre-clinical evidence Experimental Antiviral
TDZD-8
Potential treatment - theoretical effect Experimental Antiviral Feb/22/2020
Deoxyrhapontin
Potential treatment - theoretical effect Experimental Antiviral Feb/22/2020
Enzaplatovir
Potential treatment - theoretical effect Experimental Antiviral Feb/22/2020
Chalcone
Potential treatment - theoretical effect Experimental Antiviral Feb/22/2020
Cinanserin
Potential treatment - theoretical effect Experimental Antiviral Feb/22/2020
IDX-184
Potential treatment - theoretical effect Experimental Antiviral Feb/28/2020
CP-3
Potential treatment - theoretical effect Experimental Antiviral Mar/03/2020
CP-4
Potential treatment - theoretical effect Experimental Antiviral Mar/03/2020
CP-5
Potential treatment - theoretical effect Experimental Antiviral Mar/03/2020
CP-6
Potential treatment - theoretical effect Experimental Antiviral Mar/03/2020